Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison, Stephen J. Rossi, Angelo H. Paredes, et al.
Hepatology (2019) Vol. 71, Iss. 4, pp. 1198-1212
Open Access | Times Cited: 234

Showing 1-25 of 234 citing articles:

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Annalisa Berzigotti, Emmanuel Tsochatzis, Jérôme Boursier, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 3, pp. 659-689
Open Access | Times Cited: 1148
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 581
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Audrey Deprince, Joel T. Haas, Bart Staels
Molecular Metabolism (2020) Vol. 42, pp. 101092-101092
Open Access | Times Cited: 368
Gut-liver axis: Pathophysiological concepts and clinical implications
Herbert Tilg, Timon E. Adolph, Michael Trauner
Cell Metabolism (2022) Vol. 34, Iss. 11, pp. 1700-1718
Open Access | Times Cited: 361
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 338
Molecular physiology of bile acid signaling in health, disease, and aging
Alessia Perino, Hadrien Demagny, Laura A. Velázquez‐Villegas, et al.
Physiological Reviews (2020) Vol. 101, Iss. 2, pp. 683-731
Open Access | Times Cited: 299
Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy
John Y.L. Chiang, Jessica M. Ferrell
AJP Gastrointestinal and Liver Physiology (2020) Vol. 318, Iss. 3, pp. G554-G573
Open Access | Times Cited: 298
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 296
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison, Peter Ruane, B. Freilich, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1262-1271
Open Access | Times Cited: 252
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Claudia Fuchs, Michael Trauner
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 7, pp. 432-450
Closed Access | Times Cited: 249
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Kalliopi Pafili, Michael Roden
Molecular Metabolism (2020) Vol. 50, pp. 101122-101122
Open Access | Times Cited: 240
Therapeutic pipeline in nonalcoholic steatohepatitis
Raj Vuppalanchi, Mazen Noureddin, Naim Alkhouri, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 6, pp. 373-392
Closed Access | Times Cited: 233
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison, Guy Neff, Cynthia D. Guy, et al.
Gastroenterology (2020) Vol. 160, Iss. 1, pp. 219-231.e1
Open Access | Times Cited: 229
Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management
Thomas Marjot, Ahmad Moolla, Jeremy Cobbold, et al.
Endocrine Reviews (2019) Vol. 41, Iss. 1, pp. 66-117
Open Access | Times Cited: 192
Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis
John Y.L. Chiang, Jessica M. Ferrell
Liver Research (2020) Vol. 4, Iss. 2, pp. 47-63
Open Access | Times Cited: 187
Microbiota and Fatty Liver Disease—the Known, the Unknown, and the Future
Sonja Lang, Bernd Schnabl
Cell Host & Microbe (2020) Vol. 28, Iss. 2, pp. 233-244
Open Access | Times Cited: 174
Therapeutic Landscape for NAFLD in 2020
Brent A. Neuschwander‐Tetri
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1984-1998.e3
Closed Access | Times Cited: 168
Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
Jonathan G. Stine, Nagambika Munaganuru, Abbey Barnard, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 11, pp. 2274-2283.e5
Open Access | Times Cited: 166
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Erik J. Tillman, Timothy P. Rolph
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 165
Gut–liver axis: barriers and functional circuits
Oliver Pabst, Mathias W. Hornef, Frank G. Schaap, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 447-461
Closed Access | Times Cited: 164
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Chander K. Negi, Pavel Babica, Lola Bajard, et al.
Metabolism (2021) Vol. 126, pp. 154925-154925
Open Access | Times Cited: 163
Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 161
Collagen biology and non‐invasive biomarkers of liver fibrosis
M.A. Karsdal, Samuel J. Daniels, Signe Holm Nielsen, et al.
Liver International (2020) Vol. 40, Iss. 4, pp. 736-750
Open Access | Times Cited: 159
Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy
Zui Tan, Hongbao Sun, Taixiong Xue, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 154
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li, Junyan Zou, Wei Ran, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 149
Page 1 - Next Page

Scroll to top